EP Patent

EP1268450A1 — Lactams substituted by cyclic succinates as inhibitors of a-beta protein production

Assigned to Bristol Myers Squibb Pharma Co · Expires 2003-01-02 · 23y expired

What this patent protects

This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to p…

USPTO Abstract

This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
EP1268450A1
Jurisdiction
EP
Classification
—
Expires
2003-01-02
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Pharma Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.